MedTrace Logo

Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib

NCT00602433 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2011-04-15

No results posted yet for this study

Summary

Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels.

This clinical trial is looking at hormone changes in women with stage IIIB or stage IV non-small cell lung cancer receiving erlotinib.

Conditions

  • Advanced Nonsmall Cell Lung Cancer

Sponsors & Collaborators

Principal Investigators

  • Jyoti D. Patel, MD · Northwestern University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00602433 on ClinicalTrials.gov